Undisclosed CD47 inhibitor / Liminatus, InnoBation Bio - LARVOL DELTA

Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments (Businesswire) - "Liminatus Pharma LLC...and Iris Acquisition Corp...announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed 'Liminatus Pharma, Inc.'....As part of the agreement the new entity is expected to develop three much-needed cancer treatments which have originated from the Thomas Jefferson University (TJU) in the US and a South Korean biotech firm, Innobation Bio Ltd. ('Innobation')....The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor....The transaction is expected to be completed in the first half of 2023."

Commercial • Licensing / partnership • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor